Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$730.52M$730.52Mderived+18.4% vs Q4 2023 Net Income-$31.08M-$31.08MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$262,873,000+38.5% Operating Incomederived$75,793,000+434.0% Operating Cash Flowderived$118,078,000−13.1% Free Cash Flowderived$102,923,000−18.3% Margins · derivedGross margin36.0%+5.2 pt vs Q4 2023
Operating margin10.4%+8.1 pt vs Q4 2023
Net margin-4.3%+11.7 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 28, 2025 · 59 d after period end